Oral orforglipron is non-inferior to glargine for cardiovascular events

Design

Phase 3, randomised, open-label, event-driven non-inferiority trial

Population

2,749 adults with type 2 diabetes, BMI 25 or more, and established cardiovascular or chronic kidney disease

Primary outcome

Time to four-point MACE (cardiovascular death, myocardial infarction, stroke, unstable angina admission)

Effect

4.2% vs 5.0%; HR 0.84 (95% CI 0.59–1.20), non-inferior at margin 1.8

ACHIEVE-4 randomised 2,749 adults with type 2 diabetes, a BMI of 25 or more and established cardiovascular or chronic kidney disease to once-daily oral orforglipron (up to the maximum tolerated dose) or titrated insulin glargine. It was open-label and designed to show non-inferiority, with a generous margin: the upper bound of the hazard ratio had to stay below 1.8. Over a median of two years, four-point MACE occurred in 4.2% on orforglipron and 5.0% on glargine (HR 0.84, 95% CI 0.59–1.20), meeting that bar.

This is a safety result, not a benefit result. The confidence interval runs from a 41% reduction to a 20% increase, so the trial cannot say orforglipron protects the heart the way some injectable GLP-1 agonists have shown in placebo-controlled outcome trials. What it does show is that a non-peptide oral agent in this class did not signal harm in a high-risk population.

The trade-offs were as expected for the class. Gastrointestinal adverse events affected 62.1% on orforglipron against 14.2% on glargine, and were the commonest reason for stopping. Clinically significant or severe hypoglycaemia was much less frequent on orforglipron (6.8% vs 19.2%). Deaths were 1.4% and 3.2%, but deaths were not the primary endpoint and should not be read as a mortality benefit.

The trial was funded by the manufacturer. Its regulatory status in India is not established in the candidate record, so treat it as an emerging option rather than one to prescribe today.

• Orforglipron met a cardiovascular safety bar against glargine; it has not shown cardiovascular benefit.
• Expect gastrointestinal effects in most patients on oral GLP-1 agonists; plan slow titration and warn in advance.
• Against basal insulin, the hypoglycaemia advantage was large: 6.8% vs 19.2% over two years.
• For a patient who needs proven cardiovascular benefit today, the agents with outcome-trial evidence remain first choice.

Why it matters

An oral, non-peptide option in this class now has cardiovascular safety data, which matters for patients who will not inject.

Don't overread it

Non-inferiority against insulin is not superiority, and the open-label design means softer outcomes could be biased.

The statistics, in plain English

A hazard ratio of 0.84 means events were 16% less frequent on orforglipron, but the 95% confidence interval (0.59 to 1.20) crosses 1.0, so the true effect could be a reduction or a modest increase. Non-inferiority was declared because the upper limit stayed below the pre-set margin of 1.8, which is wide by design.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.